NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
The most recent EPS for Neogenomics Inc is $0.01, beating expectations of $0.0.
How did Neogenomics Inc NEO's revenue perform in the last quarter?
Neogenomics Inc revenue for the last quarter is $0.01
What is the revenue estimate for Neogenomics Inc?
According to 13 of Wall street analyst, the revenue estimate of Neogenomics Inc range from $207.53M to $189.43M
What's the earning quality score for Neogenomics Inc?
Neogenomics Inc has a earning quality score of B+/50.6915. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Neogenomics Inc report earnings?
Neogenomics Inc next earnings report is expected in 2026-07-27
What are Neogenomics Inc's expected earnings?
Neogenomics Inc expected earnings is $186.35M, according to wall-street analysts.
Did Neogenomics Inc beat earnings expectations?
Neogenomics Inc recent earnings of $186.67M beat expectations.